Welcome to our dedicated page for Inovio Pharmaceu SEC filings (Ticker: INO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inovio Pharmaceuticals filings document the regulatory record for a Nasdaq-listed biotechnology company developing DNA medicines for HPV-related diseases, cancer and infectious diseases. Form 8-K disclosures cover financial results, business updates, material agreements, at-the-market offering activity, warrant amendments and changes affecting security-holder rights.
Proxy materials describe shareholder voting matters, board governance, executive compensation and equity-award disclosures. The filing record also identifies the company’s registered common stock and capital-structure instruments, including common stock, Series A warrants and pre-funded warrants tied to public financing activity.
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing DNA medicines and CELLECTRA delivery devices, with lead candidate INO-3107 for recurrent respiratory papillomatosis (RRP). In a completed Phase 1/2 trial of INO-3107, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following treatment versus the year prior.
For the quarter and six months ended June 30, 2025, the company reported net losses of $23.5 million and $43.2 million, respectively, with net loss per share of $0.61 for the quarter and $1.12 year-to-date. Cash and cash equivalents were $24.35 million and short-term investments were $23.20 million (combined $47.5 million). Working capital was $21.0 million, total assets $68.24 million, total stockholders' equity $28.53 million, and accumulated deficit $1.773 billion.
The company disclosed substantial doubt about its ability to continue as a going concern beyond Q2 2026, but closed a July 7, 2025 underwritten public offering that generated $22.5 million of net proceeds. Management resolved a prior manufacturing issue for a CELLECTRA disposable component and completed Design Verification testing.